Featured Research

from universities, journals, and other organizations

Optimizing brachytherapy dose on the same day as the implant can control prostate cancer

Date:
June 23, 2010
Source:
Elhuyar Fundazioa
Summary:
Ensuring the optimum radiation dose on the same day as the brachytherapy implant in prostate cancer treatment manages to control the illness in about 95% of the cases, according to new research.

Ensuring the optimum radiation dose on the same day as the brachytherapy implant in prostate cancer treatment manages to control the illness in about 95% of the cases. This is the result of research undertaken at the University Hospital of Navarre and published in the latest issue of Brachytherapy, journal of the American Society of Brachytherapy.

As is known, brachytherapy is a radiotherapy treatment involving the insertion of radioactive sources within or near the tumour.

Between 2000 and 2006 the research team analysed the cases of 220 patients suffering from low-risk prostate cancer and who had been treated with iodine-125 brachytherapy seed. The researchers aimed to elucidate the parameters that influence curing amongst these patients. In the case of prostate cancer a long period of observation is required in order to obtain results, "because it is an illness in which relapse problems may occur after 5 years subsequent to the treatment," pointed out Doctor Rafael Martνnez-Monge, Director of the Department of the Radiotherapy Oncology Clinic.

Twenty percentage points difference in risk of relapse

Thus the research demonstrated that the radiation dose given during brachytherapy influences patient survival. They found a reliable parameter. They observed that on the day of the brachytherapy implant, those patients with a projected dose less than 147 Gy (gray -- Gy -- is the unit of radiation dose) showed a greater risk of relapse than those with 147 Gy or more. In concrete, they achieved control of the illness in 94.4% of those patients with an optimum implant level, compared to 75.5% amongst those who had a dose less than 147 Gy. This represents almost twenty percentage points difference and it should be remembered that an optimum implant means cure in 95% of the cases.

Moreover, another novel aspect of the research was the study on calculating the radiation dose on the same day of the implant. The international recommendation is that this calculation be carried out 30 days after, because the insertion of the radioactive seeds causes inflammation of the prostate and thus may distort the calculation. In most cases this inflammation disappears after a month. "Nevertheless, at the University Hospital of Navarre, we wish to know from the very day of the implant if the dose is suitable; otherwise, we can make an on-the-spot adjustment, both to ensure the efficacy of the treatment as well as to avoid any subsequent displacement to the patient," explained Doctor Martνnez-Monge.


Story Source:

The above story is based on materials provided by Elhuyar Fundazioa. Note: Materials may be edited for content and length.


Journal Reference:

  1. Raquel Ciervide, Miren Gaztanaga, Inigo San Miguel, Maria Esperanza Rodriguez, Nestor Montesdeoca, Juan Alcalde, Mauricio Cambeiro, Rafael Martinez-Monge. Perioperative High-Dose-Rate Brachytherapy in Locally Advanced and Recurrent Head and Neck Cancer. Brachytherapy, 2010; 9: S44 DOI: 10.1016/j.brachy.2010.02.055

Cite This Page:

Elhuyar Fundazioa. "Optimizing brachytherapy dose on the same day as the implant can control prostate cancer." ScienceDaily. ScienceDaily, 23 June 2010. <www.sciencedaily.com/releases/2010/06/100623085837.htm>.
Elhuyar Fundazioa. (2010, June 23). Optimizing brachytherapy dose on the same day as the implant can control prostate cancer. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2010/06/100623085837.htm
Elhuyar Fundazioa. "Optimizing brachytherapy dose on the same day as the implant can control prostate cancer." ScienceDaily. www.sciencedaily.com/releases/2010/06/100623085837.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) — The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) — Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) — America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) — A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:  

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile iPhone Android Web
          Follow Facebook Twitter Google+
          Subscribe RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins